3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
341
Ovarian Neoplasms
177
Lung Neoplasms
171
Breast Neoplasms
118
Fallopian Tube Neoplasms
87
Neoplasms
79
Carcinoma, Ovarian Epithelial
69
Squamous Cell Carcinoma of Head and Neck
51
Small Cell Lung Carcinoma
49
Triple Negative Breast Neoplasms
41
Adenocarcinoma of Lung
41
Head and Neck Neoplasms
40
Neoplasm Metastasis
37
Neuroblastoma
34
Central Nervous System Neoplasms
33
Endometrial Neoplasms
28
Esophageal Neoplasms
27
Carcinoma
27
Brain Neoplasms
27
Lymphoma
26
Recurrence
25
Parkinson Disease 4, Autosomal Dominant Lewy Body
25
Lymphoma, Large B-Cell, Diffuse
25
Urinary Bladder Neoplasms
24
Adenocarcinoma, Bronchiolo-Alveolar
23
Testicular Neoplasms
22
Astrocytoma
22
Melanoma
19
Uterine Cervical Neoplasms
18
Prostatic Neoplasms
18
Interventions
pembrolizumab
6
Nivolumab
6
Ipilimumab
4
Radiotherapy
3
talimogene laherparepvec
2
budigalimab
2
avelumab
2
atezolizumab
2
Everolimus
2
Cyclophosphamide
2
zimberelimab
1
venetoclax
1
vatalanib
1
tremelimumab
1
temsirolimus
1
sapanisertib
1
rovalpituzumab tesirine
1
poly ICLC
1
oblimersen
1
lorvotuzumab mertansine
1
lanreotide
1
glucopyranosyl lipid-A
1
fludarabine
1
durvalumab
1
domatinostat
1
cixutumumab
1
cemiplimab
1
aldesleukin
1
Vinorelbine
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Merkel Cell
×
Carboplatin
×
Clear all
NCT01013779
2022-11-18
MP3
Trans Tasman Radiation Oncology Group
Phase 2
Completed
43 enrolled